Literature DB >> 12525254

Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei.

M E Pyle1, M Korbonits, M Gueorguiev, S Jordan, B Kola, D G Morris, A Meinhardt, M P Powell, F X Claret, Q Zhang, C Metz, R Bucala, A B Grossman.   

Abstract

Macrophage migration inhibitory factor (MIF) is an essential regulator of the macrophage responses to endotoxin. MIF also has the ability to override the anti-inflammatory actions of glucocorticoids during an immune response, and is thus an important pro-inflammatory factor. The presence of MIF in cells of the anterior pituitary has been described, and high levels of MIF in other rapidly proliferating tIssues have also been demonstrated. It has been hypothesised that MIF release from these cells is influenced by the hypothalamo-pituitary-adrenal axis, and that ACTH and MIF are released simultaneously to exert counter-regulatory effects on cortisol. However, another intracellular role for MIF has also been suggested as it has been shown that MIF exerts an effect on the inhibitory cell cycle control protein p27 through an interaction with Jab1, a protein implicated in p27 degradation. We studied MIF expression in different normal and adenomatous human pituitary samples using immunohistochemistry and RT-PCR. There was evidence of co-immunoprecipitation of MIF with Jab1, suggesting an interaction of the two proteins. Our results showed that there is increased expression of MIF protein in the nuclei of all pituitary adenomas compared with normal tIssue (P=0.0067), but there was no statistically significant difference in nuclear MIF expression between the different adenoma types. Nuclear MIF expression correlated positively with p27 and its phosphorylated form in normal tIssue (P=0.0028 and P<0.0001); however, this relationship was not seen in the adenoma samples. Cytoplasmic expression of MIF was found to be variable both in normal and adenomatous samples, with no consistent pattern. MIF mRNA was demonstrated to be present in all tumour and normal samples studied. Somatotroph tumours showed higher MIF mRNA expression compared with normal pituitary or other types of adenomas. In conclusion, MIF is expressed in cell nuclei in pituitary adenomas to a greater extent than in normal pituitary tIssue. We speculate that it may play a role in the control of the cell cycle, but whether its higher level in adenomas is a cause or a consequence of the tumorigenic process remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525254     DOI: 10.1677/joe.0.1760103

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  10 in total

1.  Clinicopathological significance of macrophage migration inhibitory factor and its relation with p53 in gastric cancer.

Authors:  Majid Nabizadeh Marvast; Hamid Reza Sima; Kamran Ghaffarzadehgan; Ali Taghizadeh Kermani; Nona Norouzi
Journal:  J Gastrointest Cancer       Date:  2011-03

2.  Oxygen regulation of macrophage migration inhibitory factor in human placenta.

Authors:  Francesca Ietta; Yuanhong Wu; Roberta Romagnoli; Nima Soleymanlou; Barbara Orsini; Stacy Zamudio; Luana Paulesu; Isabella Caniggia
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-08-29       Impact factor: 4.310

3.  Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas.

Authors:  Chia-Tung Shun; Jaw-Town Lin; Shih-Pei Huang; Min-Tsan Lin; Ming-Shiang Wu
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

4.  Expression of macrophage migration inhibitory factor in the mouse neocortex and posterior piriform cortices during postnatal development.

Authors:  Wei Zhang; Lingling Li; Jiutao Wang; Lei An; Xinde Hu; Jiongfang Xie; Runchuan Yan; Shulin Chen; Shanting Zhao
Journal:  Cell Mol Neurobiol       Date:  2014-08-14       Impact factor: 5.046

5.  The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.

Authors:  Hakan Camlica; Derya Duranyildiz; Hilal Oguz; Ethem Nezih Oral; Vildan Yasasever
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

6.  The conformational flexibility of the carboxy terminal residues 105-114 is a key modulator of the catalytic activity and stability of macrophage migration inhibitory factor.

Authors:  Farah El-Turk; Michele Cascella; Hajer Ouertatani-Sakouhi; Raghavendran Lakshmi Narayanan; Lin Leng; Richard Bucala; Markus Zweckstetter; Ursula Rothlisberger; Hilal A Lashuel
Journal:  Biochemistry       Date:  2008-09-17       Impact factor: 3.162

7.  Characterization of molecular determinants of the conformational stability of macrophage migration inhibitory factor: leucine 46 hydrophobic pocket.

Authors:  Farah El-Turk; Bruno Fauvet; Amer Ashrafi; Hajer Ouertatani-Sakouhi; Min-Kyu Cho; Marilisa Neri; Michele Cascella; Ursula Rothlisberger; Florence Pojer; Markus Zweckstetter; Hilal Lashuel
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

8.  Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Authors:  Ramona Schulz; Natalia D Marchenko; Lena Holembowski; Günter Fingerle-Rowson; Marina Pesic; Lars Zender; Matthias Dobbelstein; Ute M Moll
Journal:  J Exp Med       Date:  2012-01-23       Impact factor: 14.307

9.  HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Authors:  R Schulz; F Streller; A H Scheel; J Rüschoff; M-C Reinert; M Dobbelstein; N D Marchenko; U M Moll
Journal:  Cell Death Dis       Date:  2014-01-02       Impact factor: 8.469

10.  MIF Plays a Key Role in Regulating Tissue-Specific Chondro-Osteogenic Differentiation Fate of Human Cartilage Endplate Stem Cells under Hypoxia.

Authors:  Yuan Yao; Qiyue Deng; Weilin Song; Huiyu Zhang; Yuanjing Li; Yang Yang; Xin Fan; Minghan Liu; Jin Shang; Chao Sun; Yu Tang; Xiangting Jin; Huan Liu; Bo Huang; Yue Zhou
Journal:  Stem Cell Reports       Date:  2016-08-09       Impact factor: 7.765

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.